Profile data is unavailable for this security.
About the company
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
- Revenue in USD (TTM)58.05bn
- Net income in USD11.78bn
- LocationAbbvie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|ABBV:NYQ since |
|DJS Antibodies Ltd||Deal completed||20 Oct 2022||20 Oct 2022Deal completed||11.35%||255.00m|
|iSTAR Medical SA||Announced||20 Jul 2022||20 Jul 2022Announced||6.43%||475.00m|